All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Abbvie Deutschland GmbH & Co. KG
Enrolment target
272
Start
06 Dec 2022
What is this study about?
Study 1 - Primary endpoint is ASAS 40 response at week 14, Study 2 - Primary endpoint is ASAS 40 response at week 14
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (9)
- —Germany
- —France
- —Bulgaria
- —Hungary
- —Poland
- —Spain
- —Slovakia
- —Czechia
- —Belgium
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.